Wong, Selina K.
Hamm, Jeremy
Shokoohi, Aria
McGahan, Colleen E.
Ho, Cheryl http://orcid.org/0000-0002-5922-3984
Article History
Received: 27 August 2020
Accepted: 17 February 2021
First Online: 2 March 2021
Ethics approval and consent to participate
: This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study received approval from the University of British Columbia BC Cancer Agency Research Ethics Board, H18–03294. There was no active enrollment or active follow-up of study subjects, and no data were collected directly from individuals. The researchers confirmed that they would take appropriate measures to protect the privacy of individuals, and to safeguard the identifiable information; comply with any known preferences previously expressed by individuals about any use of their information; acknowledged that it was impracticable to seek consent from individuals to whom the information relates; and obtained necessary permission for secondary use of information for research purposes to receive a waiver of consent from the REB for our retrospective study. Administrative permission from the BC Cancer Registry was granted to access the raw data used in the study.
: Not applicable.
: Dr. Ho reports grants and personal fees from Astra Zeneca, personal fees and other from Boehringer Ingelheim, personal fees from BMS, personal fees and other from Roche, grants and personal fees from Eisai, personal fees from Merck, personal fees from Bayer, personal fees from Novartis, outside the submitted work. The remaining authors declare that they have no conflict of interest.